Q
QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

27,875 signal articles · 230 in last 24h · 135,230 total before filter · latest 37m ago
230last 24h
1106last 7d
175● bullish (7d)
149● bearish (7d)
209publishers
AllMacro303Earnings357M&A79Regulatory26Product11Analyst16
✕ clear all filterssentiment: neutralSentiment:bullishneutralbearishshow all (incl. clickbait)
Bath & Body Works Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Bath & Body Works Q2 Earnings Call Highlights

Bath & Body Works (NYSE:BBWI) reported second-quarter results that exceeded its prior outlook, though sales remained under pressure as the retailer invests in product innovation, marketing, digital capabilities and expanded distribution to support a planned return to revenue growth in 2027. Net

Abercrombie & Fitch Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Abercrombie & Fitch Q2 Earnings Call Highlights

Abercrombie & Fitch (NYSE:ANF) reported record second-quarter fiscal 2026 net sales of $1.27 billion, up 5% from a year earlier, as growth across regions and brands exceeded the company’s prior outlook. The retailer also raised its full-year sales, operating-margin and earnings-per-share expecta

Li Auto Q2 Earnings Call Highlights
MarketBeat9d agoneutral
Li Auto Q2 Earnings Call Highlights

Li Auto (NASDAQ:LI) reported a second-quarter net loss as revenue and vehicle margins declined from a year earlier, while management outlined plans for new battery-electric vehicle launches, continued investment in proprietary technology and expansion into overseas markets. Total revenue for the se

Anthropic Says Its Market Is $30 Trillion, Same As US GDP
24/7 Wall St.9d agoneutral
Anthropic Says Its Market Is $30 Trillion, Same As US GDP

Anthropic is pitching investors a revenue number so large it strains belief, but buried beneath the headline figure lies a tangle of risks involving overbuilt data centers, geopolitical threats, and an AI economy that could ultimately devour the very consumers it depends on.

Banks Fought Against Stablecoins. Now They Are Considering Launching Their Own.
The Wall Street Journal9d agoneutral
Banks Fought Against Stablecoins. Now They Are Considering Launching Their Own.

Banks large and small have started to warm up to the idea of their own stablecoins, despite early doubts from some executives that there will be much demand for them. Instead, banks banded together to launch a tokenized deposit system as an answer to the rapid changes in the world of payments. Stablecoins are digital tokens pegged to the U.S. dollar or other currencies, while tokenized deposits are just traditional money represented as digital tokens.

What’s Moving the Markets Today?
The Wall Street Journal9d agoneutral
What’s Moving the Markets Today?

What a lot of market watchers are wondering today is: What’s next for the AI boom? Nvidia’s results don’t move the market like they used to, And over the last four quarters, Nvidia’s share price has averaged a 2.8% loss the day after earnings. Stay tuned for deep coverage of Nvidia’s earnings report when it releases this afternoon.

Investing.com9d agoneutral
Palo Alto Networks CEO held acquisition talks with both Okta and Datadog

The Information reported that between late 2024 and early 2025, Arora held a series of meetings with Okta CEO Todd McKinnon. The talks progressed to the point where the companies discussed product complementarity, but ultimately stalled over price disagreements, according to people with knowledge of the discussions cited by The Information. Okta, valued at roughly $13.5 billion at the start of last year, has since climbed around 30%, giving it a market cap near $23 billion.

FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking
Benzinga9d agoneutral
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

The U.S. Food and Drug Administration (FDA) on Tuesday approved Abbott Laboratories’ (NYSE:ABT) Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for diabetes patients aged two and older. The regulatory nod makes the device the first wearable in the U.S. to monitor ketone levels continuously. It also represents the first global system to track blood sugar and ketones simultaneously within a single unit. Clinical Data And De Novo Pathway The agency granted marketing authorization

Abercrombie & Fitch raises full-year outlook as Q2 earnings top estimates
Proactive9d agoneutral
Abercrombie & Fitch raises full-year outlook as Q2 earnings top estimates

Abercrombie & Fitch (NYSE:ANF) shares rose about 13% on Wednesday after the apparel retailer reported second quarter fiscal 2026 results that exceeded Wall Street expectations and raised its full-year outlook. The company reported adjusted earnings per diluted share of $4.17, compared...